The importance of clinical epidemiology for development of appropriate treatment modalities for asian populations

Asian Pacific Journal of Cancer Prevention

Volumn 8, Issue 1, 2007, Pages 146-147

  Kawahara, Norie ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Asian countries; Clinical epidemiology; Influencing factors; Treatment efficacy

Indexed keywords

ASIA; ETHNIC GROUP; GENETIC POLYMORPHISM; HUMAN; INCIDENCE; MASS SCREENING; NEOPLASM; REVIEW; RISK FACTOR;

ASIA; ETHNIC GROUPS; HUMANS; INCIDENCE; MASS SCREENING; NEOPLASMS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 34547809434     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Note

References (10)

1. Akaza H, Moore MA, Cheng S-J, et al (2007). The 5th conference on Asia trends in prostate cancer hormone therapy. Asian Pac J Cancer Prev, 8, 1-2.
2. Edelman MJ, Sekine I, Tamura T, Saijo N (2006). Geographic variation in the second-line treatment of non-small cell lung cancer. Semin Oncol, 33 (1 Suppl 1), S39-44.
3. Kakizoe T (2003). Chemoprevention of cancer - focusing on clinical trials. Jpn J Clin Oncol, 33, 421-42.
4. Kelsey KT, Ross D, Traver RD, et al (1997). Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anticancer chemotherapy. Br J Cancer, 76, 852-4.
5. Leung TW (2007). Ethnic aspects of cancer trials in Asia. Ernst Schering Res Found Workshop, 59, 165-9.
6. Ma B, Yeo W, Hui P, Ho WM, Johnson PJ (2002). Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer -- a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol, 62, 185-9.
7. Marsh S, Collie-Duguid ES, Li T, Liu X, McLeod HL (1999). Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics, 58, 310-2.
8. McCollum AD, Catalano PJ, Haller DG, et al (2002). Outcomes and toxicity in African-American and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst, 94, 1160-7.
9. Moore MA, Tajima, K (2006). Establishment of the UICC Asia Regional office and directions for collaborative efforts in the future. Asian Pac J Cancer Prev, 7, 345-7.
10. Park K, Goto K (2006). A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin, 22, 561-73.